design

What Are the Challenges of Using Data Directly From the EHRs?

Posted on by Elizabeth Mccamic

What Are the Challenges of Using Data Directly From the EHRs?

Description

Dr. Rachel Richesson discusses the challenges of using data directly from the electronic health records (EHRs), including differences in systems different data coding and representation conventions.

Speaker

Rachel Richesson, PhDHeadshot of Rachel Richesson
Professor of Learning Health Sciences, University of Michigan Medical School
Electronic Health Records Core Co-chair

 

Related

What Is A Computable Phenotype?

What Are the Benefits to Standardizing Phenotype Definition?

What Are the Key Factors in Using EHR Data for Endpoints and Outcomes?

Using Electronic Health Record Data in Pragmatic Clinical Trials

What Are the Arguments For and Against the Stepped-Wedge Design?

Posted on by Elizabeth Mccamic

What Are the Arguments For and Against the Stepped-Wedge Design?

Description

Dr. Liz Turner discusses arguments for and against using the stepped-wedge design when choosing the right cluster randomized trial in pragmatic research. Turner recommends if possible, using a parallel design, but if a stepped-wedge design is necessary, plan for time effects in design and analysis.

Speaker

Liz Turner, PhD
Associate Professor, Biostatistics and Bioinformatics and Global Health
Biostatistics and Study Design Core Co-Chair

 

 

Related

What Are the Types of CRT Designs?

What Is An Example of How to Choose a Study Design?

What Is the Intraclass Correlation Coefficient?

Posted on by Elizabeth Mccamic

What Is the Intraclass Correlation Coefficient?

Description

Dr. Liz Turner discusses the Intraclass Correlation Coefficient (ICC), which is the measure between-cluster outcome variability relative to the overall variability in the system.

Speaker

Liz Turner, PhD
Associate Professor, Biostatistics and Bioinformatics and Global Health
Biostatistics and Study Design Core Co-Chair

 

Related

What Are the Reasons to Randomize Clusters Instead of Individuals?

What Is Outcome Clustering, and How Can It Affect a Trial?

How Does Clustering Affect Power and Detectable Difference?

How Do You Estimate the Degree of Clustering for Outcomes?

Photo of Greg Simon

Engaging With Stakeholders in Pragmatic Clinical Trials

Posted on by terren.green@duke.edu

Engaging With Stakeholders in Pragmatic Clinical Trials

Description

In this video, Dr. Greg Simon shares how to engage with a range of stakeholders, both early and throughout the process of pragmatic clinical trials. Stakeholders at the local site will have practical advice about how to get the research done, and healthcare system leaders may be more interested in the value added by the research.

Speaker

Gregory Simon, MD, MPH
Senior Investigator, Kaiser Permanente Washington Health Research Institiute
SPOT NIH Collaboratory Trial PI
Health Care Systems Interactions Core Chair
Coordinating Center Leadership

Related

Embedded ePCT Team Composition

What Is A Computable Phenotype?

Posted on by Elizabeth Mccamic

What Is A Computable Phenotype?

Description

Dr. Rachel Richesson discusses the specifications of defining computable phenotypes. This term is often used to identify patients for a study or to identify conditions that serve as outcomes of various studies.

Speaker

Rachel Richesson, PhDHeadshot of Rachel Richesson
Professor of Learning Health Sciences, University of Michigan Medical School
Electronic Health Records Core Co-chair

 

Related

What Are the Challenges of Using Data Directly From the EHRs?

What Are the Benefits to Standardizing Phenotype Definition?

What Are the Key Factors in Using EHR Data for Endpoints and Outcomes?

Using Electronic Health Record Data in Pragmatic Clinical Trials

What Is An Example of How to Choose a Study Design?

Posted on by Elizabeth Mccamic

What Is An Example of How to Choose a Study Design?

Description

Dr. Liz Turner provides a framework for choosing a study design by discussing the design of SPOT, STOP CRC, LIRE, and OPTIMUM, which are all NIH Collaboratory Trials within the Collaboratory. Turner shares similarities and differences regarding the design of these trials to aid researchers in making decisions about the most effective study design for their trial.

Speaker

Liz Turner, PhD
Associate Professor, Biostatistics and Bioinformatics and Global Health
Biostatistics and Study Design Core Co-Chair

 

 

Related

What Are the Types of CRT Designs?

What Are the Arguments For and Against the Stepped-Wedge Design?

What Are Endpoints and Outcomes?

Posted on by Elizabeth Mccamic

What Are Endpoints and Outcomes?

Description

Dr. Devon Check discusses the difference between endpoints and outcomes in pragmatic clinical trials with endpoints referring to change in a measured variable and outcome describing the variable itself.

Speaker

Devon Check, PhD

Devon Check, PhD
Assistant Professor, Population Health Sciences
Duke University School of Medicine
Implementation Science Core Co-Chair

 

Related

What Do Endpoints And Outcomes Look Like in Pragmatic Trials?

How Do Data Sources Inform the Choice of Endpoints and Outcomes in Pragmatic Trials?

 

What Is Outcome Clustering, and How Can It Affect a Trial?

Posted on by Elizabeth Mccamic

What Is Outcome Clustering, and How Can It Affect a Trial?

Description

In this video, Dr. Liz Turner demystifies the notions of outcome clustering, which for a pragmatic trial might mean clustering at the level of a clinic and an intervention.

Speaker

Liz Turner, PhD
Associate Professor, Biostatistics and Bioinformatics and Global Health
Biostatistics and Study Design Core Co-Chair

 

 

Related

What Are the Reasons to Randomize Clusters Instead of Individuals?

What Is the Intraclass Correlation Coefficient?

How Does Clustering Affect Power and Detectable Difference?

How Do You Estimate the Degree of Clustering for Outcomes?

What Are Common Pitfalls in Writing PCT Grant Applications?

Posted on by Elizabeth Mccamic

What Are Common Pitfalls in Writing PCT Grant Applications?

Description

Dr. Wendy Weber discusses common concerns expressed during the peer review process for writing PCT grant application and provides application recommendations from a reviewer's perspective.

Speaker

Wendy Weber, ND, PhD, MPH
Branch Chief, Clinical Research Branch
Division of Extramural Research
National Center for Complementary and Integrative Health (NCCIH)

 

Related

Is It Important to Explain the Definition of Pragmatic to Grant Reviewers?

What Are the “Must Dos” of Writing PCT Grant Applications?

What Should I Avoid When Writing PCT Grant Applications?

What Are Some Success Strategies for Writing PCT Grant Applications?

Developing a Compelling Grant Application

How Do You Estimate the Degree of Clustering for Outcomes?

Posted on by Elizabeth Mccamic

How Do You Estimate the Degree of Clustering for Outcomes?

Description

Dr. Liz Turner discusses estimating the degree of clustering for outcomes, starting with consulting other studies with similar settings and looking in the EHRs to see what data is available to inform and give a preliminary estimate of the ICC.

Speaker

Liz Turner, PhD
Associate Professor, Biostatistics and Bioinformatics and Global Health
Biostatistics and Study Design Core Co-Chair

 

Related

What Are the Reasons to Randomize Clusters Instead of Individuals?

What Is Outcome Clustering, and How Can It Affect a Trial?

What Is the Intraclass Correlation Coefficient?

How Does Clustering Affect Power and Detectable Difference?